Manufacturers report positive results for lasmiditan for migraine in phase 3 study

The CENTURION study found that 200 mg lasmitidan (a 5-HT1F receptor agonist) improved the odds of achieving pain freedom at 2 hours in at least 2 of 3 migraine attacks (co-primary endpoint) than those on placebo (24.4% vs. 4.3%; OR 7.2; p<0.001).

Biospace Inc.